Zimmer Biomet Holdings, Inc. is a medical technology company valued at $20.4 billion, serving orthopedic and neurosurgeons, hospitals, and healthcare specialists. Despite underperforming the market, their Q2 earnings released on Aug. 7 showed revenue growth of 7% and an EPS of $2.07, surpassing expectations. Analysts predict a 2% EPS growth for the fiscal year.

Following their strong quarterly performance, 28 analysts covering the stock give it a consensus rating of “Moderate Buy,” with a mean price target of $109.58 and a street-high target of $138. Morgan Stanley analyst Patrick Wood maintained a “Hold” rating with a price target of $100, suggesting an ambitious upside potential of 34.3%.

Read more at Yahoo Finance: Do Wall Street Analysts Like Zimmer Biomet Stock?